natgillin/translations-raw huggingface dataset:
the graft attacks your body (graft versus host disease) respiratory complications
presadek napade vaše telo (reakcija presadka proti gostitelju) zapleti pri dihanju
the graft may detach completely or partially from the defect in the joint.
pretirana rast hrustanca, vsadek se lahko povsem ali delno odcepi od okvare v sklepu.
The granules are small off white/ light brown coloured approximately 1.5mm diameter.
Zrnca so majhna, umazano bele/svetlorjave barve in imajo premer približno 1,5 mm.
The granules left in the spoon are one spoonful
Zrnca, ki ostanejo v žlički so ena merica.
The granules should be dissolved in a glass of cool water, and the resulting buffer solution should be mixed with the vaccine.
Zrnca je treba raztopiti v kozarcu hladne vode in dobljeno pufrsko raztopino zmešati s cepivom.
The granules should not be crushed or chewed.
Zrnca se ne smejo drobiti ali žvečiti.
The greatest amelioration was seen in the domains of practical problems and daily activities limited by symptoms.
Največje izboljšanje je bilo doseženo na področju praktičnih težav in vsakodnevnih dejavnosti, ki so jih omejevali simptomi.
The greatest benefit was observed in the subgroup of 49 patients with EGFR activating mutations: those taking Tarceva (22 patients) lived for an average of 44.6 weeks without their disease getting worse, compared with 13 weeks for those taking placebo (27 patients).
Največje koristi so opazili pri podskupini 49 bolnikov z EGFR-aktivirajočimi mutacijami: bolniki, ki so jemali zdravilo Tarceva (22 bolnikov), so v povprečju živeli 44,6 tedna, preden je prišlo do poslabšanja bolezni, v primerjavi s 13 tedni pri tistih, ki so jemali placebo (27 bolnikov).
The greatest effects are observed in patients with low haemoglobin (≤ 13 g/dl).
Največje učinke so opazili pri bolnikih z nizkim hemoglobinom (≤ 13 g/dl).
The greatest elevation of dabigatran exposure was observed with the first dose of an immediate release formulation of verapamil administered one hour prior to dabigatran etexilate intake (increase of Cmax by about 180 % and AUC by about 150 %).
Izpostavljenost dabigatranu se je najbolj povečala po prvem odmerku oblike verapamila s takojšnjim sproščanjem, danega eno uro pred jemanjem dabigatran eteksilata (Cmax se je povečala za približno 180 %, AUC pa za približno 150 %).
The greatest mean change from baseline (21 bpm) occurs approximately 1 minute after administration of Rapiscan.
Največja srednja sprememba od izhodišča (21 utripov/minuto) se pojavi približno 1 minuto po dajanju zdravila Rapiscan.
The greatest risk of hepatic and skin reactions occurs in the first 6 weeks of therapy.
Nevarnost jetrnih dogodkov in kožnih reakcij je največja prvih 6 tednov zdravljenja.
The green 10 microgram Lyxumia pen is empty when the black plunger has reached ‘0’ on the dose scale and the injection button cannot be pulled out fully.
Zeleni peresnik Lyxumia 10 mikrogramov je prazen, ko črni bat doseže oznako "0" na merilu odmerka in se gumba za injiciranje ne da več povsem izvleči.
The green control window confirms that your medicinal product is ready for inhalation.
Zeleno kontrolno okence potrdi, da je zdravilo pripravljeno za inhaliranje.
The green control window confirms that your medicine is ready for inhalation.
Zeleno kontrolno okence potrdi, da je zdravilo pripravljeno za inhaliranje.
The green indicator shows the progress of the injection.
Zeleni indikator kaže potek injiciranja.
The green light will switch off and the number of doses delivered will flash on and off.
Zelena lučka ugasne in število dovedenih odmerkov utripa.
The green pen contains 14 pre-set doses; each dose contains 10 micrograms of Lyxumia.
Zeleni peresnik vsebuje 14 prednastavljenih odmerkov; vsak odmerek vsebuje 10 mikrogramov zdravila Lyxumia.
The green plunger rod should show through the body of the syringe.
Zeleni potisni bat mora biti viden skozi ohišje brizge.
The green stripes will be moving in the injection status window.
V okencu za stanje injiciranja se premikajo zelene črte.
The grey needle cap on the Repatha pre-filled syringe is composed of dry natural rubber, which is made from latex.
Sivi pokrovček igle na napolnjeni injekcijski brizgi zdravila Repatha je narejen iz suhe naravne gume, ki je izdelana iz lateksa.
The grey syringe plunger should be pushed all the way to the needle end of the syringe.
Sivi bat brizge morate potisniti vse do konca brizge, kjer se nahaja igla.
The GSS was obtained from the Monogram reports with susceptible virus ascribed the values ‘1-4’ based upon the numbers of drugs in the regimen and with virus with reduced susceptibility ascribed the value ‘0’.
GSS so bile dobljene iz poročil Monogram; občutljivim virusom so bile dodeljene vrednosti "1-4", odvisno od števila zdravil v shemi, virusom z zmanjšano občutljivostjo pa je bila pripisana vrednost "0".
The guide for HCPs and Blood Banks, to advice about the risk of interference for blood typing and how to minimise it;
Vodnik za za zdravstvene delavce in krvno banko s podatki o tveganju za motnje pri tipizaciji krvi in navodili, kako minimizirati to tveganje;
The guide for pharmacists, containing the following key elements:
Vodnik za farmacevte, ki vsebuje naslednje ključne točke:
The guide for physicians shall contain the following key elements:
Vodnik za zdravnike mora vsebovati naslednje ključne točke:
the haemangioma is ulcerated and painful, and/or does not respond to simple wound care measures; there is a risk of permanent scars or disfigurement.
je hemangiom ulceriran in boleč in/ali se ne odziva na enostavne ukrepe pri oskrbi rane, obstaja tveganje za trajne brazgotine ali izmaličenje.
The haematological adverse reactions observed in the clinical studies with Xofigo are much lower in frequency and severity than what could be expected from the calculated absorbed doses to the red marrow.
Hematološki neželeni učinki zdravila, ki so jih opazili v kliničnih študijah z zdravilom Xofigo, so manj pogosti in manj hudi, kot jih je pričakovati iz izračunanih absorbiranih doz za rdeči kostni mozeg.
The haematological toxicity for ovarian cancer patients is less severe than in the AIDS-KS setting (see section for ovarian cancer patients above).
Hematološki toksični učinki pri bolnicah z rakom jajčnikov so manj hudi kot pri bolnikih, ki imajo z aidsom povezan Kaposijev sarkom (glejte poglavje o bolnicah z rakom jajčnikov).
The haemoglobin concentration aimed for is between 10 and 12 g/dl (6.2-7.5 mmol/l), except in paediatric patients in whom the haemoglobin concentration should be between 9.5 and 11 g/dl (5.9-6.8 mmol/l).
Ciljna koncentracija hemoglobina je med 10 in 12 g/dl (6,2–7,5 mmol/l), razen pri pediatričnih bolnikih, kjer mora biti koncentracija hemoglobina med 9,5 in 11 g/dl (5,9–6,8 mmol/l).
The haemoglobin values should not exceed a value of 12 g/dl
Vrednosti hemoglobina ne smejo preseči 12 g/dl.
The haemoglobin values should not exceed a value of 12 g/dl.
Vrednosti hemoglobina ne smejo preseči 12 g/dl.
The haemolytic anaemia may affect a patient’s heart function and lead to abnormal test values for substances such as uric acid and bilirubin in the blood.
Vpliva lahko na bolnikovo delovanje srca in povzroči neobičajne vrednosti pri testiranjih za snovi kot sta sečna kislina in bilirubin v krvi.
The haemorrhagic reactions that have been observed in clinical trials were predominantly tumour- associated haemorrhage (see below) and minor mucocutaneous haemorrhage (e.g. epistaxis).
Krvavitve, ki so jih opazili v kliničnih preskušanjih, so bile večinoma krvavitve, povezane s tumorjem (glejte spodaj), in manjše kožne in sluznične krvavitve (na primer epistaksa).
The half life of tocilizumab in sJIA patients is up to 23 days for the two body weight categories (8 mg/kg for body weight ≥ 30 kg or 12 mg/kg for body weight < 30 kg) at week 12.
Razpolovni čas tocilizumaba pri bolnikih s sJIA je v 12. tednu do 23 dni za obe skupini, ločeni glede na telesno maso (8 mg/kg tocilizumaba za bolnike s telesno maso ≥ 30 kg ali 12 mg/kg za bolnike s telesno maso < 30 kg).
The half life, clearance and volume of distribution were similar at both dose levels.
Razpolovni čas, očistek in volumen porazdelitve so bili podobni pri obeh višinah odmerkov.
The half-life may vary from patient to patient, particularly in PID.
Razpolovni čas se lahko pri bolnikih razlikuje, predvsem pri tistih s PID.
The half-life of ciclosporin was increased by 33% when coadministered with levofloxacin.
Razpolovni čas ciklosporina se je med sočasno uporabo levofloksacina podaljšal za 33%.
The half-life of insulin degludec is approximately 25 hours and the half-life of liraglutide is approximately 13 hours.
Razpolovni čas insulina degludek je približno 25 ur, razpolovni čas liraglutida pa približno 13 ur.
The half-life of Kengrexal is three to six minutes, independent of dose.
Razpolovni čas zdravila Kengrexal je tri do šest minut, neodvisno od odmerka.
The half-life of the basal component (insulin degludec) at steady state is 25 hours independent of dose.
Razpolovni čas bazalne sestavine (insulina degludek) v stanju dinamičnega ravnovesja je 25 ur, ne glede na odmerek.
The handling of liquid nitrogen should take place in a well-ventilated area.
S tekočim dušikom je treba delati v dobro zračenem prostoru
The handling of liquid nitrogen should take place in a well-ventilated area.
S tekočim dušikom je treba delati v dobro zračenem prostoru.
The hard capsule consists of a rich yellow body and cap bearing the black imprint “OS 30”.
Trda kapsula ima rumeno neprozorno telo ” in pokrov s črnim napisom “OS 30”.
The hard capsule consists of a white opaque body and a rich yellow cap bearing the black imprint “OS 75”.
Trda kapsula ima motno belo telo in rumen neprozorni pokrov s črnim napisom “OS 75”.
The hard capsule consists of a white opaque body and cap bearing the black imprint “OS 45”.
Trda kapsula ima motno belo telo in pokrov s črnim napisom “OS 30”.
The hard capsule consists of a white opaque body and cap bearing the black imprint “OS 45”.
Trda kapsula ima motno belo telo ” in pokrov s črnim napisom “OS 45”.
The hard capsule shell is composed of gelatin, titanium dioxide (E171), red and yellow iron oxide (E172) and, shellac and black iron oxide (E172) for stamping of the imprint.
Ovojnica trde kapsule je iz želatine, titanovega dioksida (E171), rdečega in rumenega železovega oksida (E172), šelaka in črnega železovega oksida (E172) za tiskanje oznake.
The hard capsule shell is composed of gelatin, titanium dioxide (E171), yellow iron oxide (E172) and, shellac (E904) and red iron oxide (E172) for stamping of the imprint.
Ovojnica trde kapsule je iz želatine, titanovega dioksida (E171), rumenega železovega oksida (E172), šelaka (E904) in rdečega železovega oksida (E172) za tiskanje oznake.
The hard capsules (length approx.
Trde kapsule (dolžine pribl.
The hard capsules are available in one amber glass bottle containing 5 or 20 capsules, and in blister packs containing 5 capsules.
Trde kapsule so na voljo v rjavih steklenicah, ki vsebujejo po 5 ali 20 kapsul, in v pretisnem omotu s 5 kapsulami.
The hard capsules are dispensed in amber glass bottles (Type 3 glass) with polypropylene child- resistant closures.
Trde kapsule so na voljo v rjavih steklenicah (steklo tipa III) z za otroke varno zaporko iz polipropilena.
The hard capsules are green/white hard gelatin capsules imprinted ‘TMZ’ on cap & ‘5’ on body.
Trde kapsule so zeleno-bele trde želatinske kapsule, z oznako 'TMZ' na kapici in oznako '5' na telesu.
The hard capsules are maroon/white, hard gelatin capsules, imprinted with ‘TMZ’ on cap & ‘180’ on body.
Trde kapsule so temno rdeče-bele trde želatinske kapsule, z oznako 'TMZ' na kapici in oznako '180' na telesu.
The hard capsules are opaque with a white body and a caramel cap with ‘HE1’ printed on the body.
Trde kapsule so neprozorne z belim telesom in pokrovčkom karamelne barve ter oznako »HE1«, odtisnjeno na telesu.
The hard capsules are pink/white hard gelatin capsules, imprinted ‘TMZ’ on cap & ‘100’ on body.
Trde kapsule so roza-bele trde želatinske kapsule, z oznako 'TMZ' na kapici in oznako '100' na telesu.
The hard capsules are transparent blue/white hard gelatin capsules, imprinted ‘TMZ’ on cap & ‘140’ on body.
Trde kapsule so prozorno modro-bele trde želatinske kapsule, z oznako 'TMZ' na kapici in oznako '140' na telesu.
The hard capsules are white, with ‘TMC435 150’ printed in black ink.
Trde kapsule so bele barve in imajo s črnim barvilom natisnjeno oznako "TMC435 150".
The hard capsules are white/white, hard gelatin capsules imprinted with ‘TMZ’ on cap & ‘250’ on body.
Trde kapsule so bele trde želatinske kapsule, z oznako 'TMZ' na kapici in oznako '250' na telesu.
The hard capsules have a white body and opaque brown cap imprinted "TC448" in grey.
Trde kapsule imajo belo telo z rjavim neprosojnim pokrovčkom in odtisom "TC448" v sivi barvi.
The hard capsules have a white coloured body, a transparent blue coloured cap, and are imprinted with black ink.
Trde kapsule imajo belo telo in prozorno modro kapico ter vtisnjen napis s črnim črnilom.
The hard capsules have a yellowish-brown cap with the "MSD" logo printed in red ink and an off- white body with "314" printed in red ink.
Zgornji del trde kapsule je rumenkasto-rjav in ima z rdečim črnilom natisnjeno oznako "MSD", spodnji del kapsule pa je sivo bel in ima z rdečim črnilom natisnjeno kodo "314".
The hard capsules should be swallowed whole.
Trde kapsule je treba pogoltniti cele.
The hard capsules should not be pushed through the blister foil.
Trdih kapsul ne smete potiskati skozi folijo na pretisnem omotu.
The hardcapsules are yellow/ white hard gelatin capsules, imprinted ‘TMZ’ on cap & ‘20’ on body.
Trde kapsule so rumeno-bele trde želatinske kapsule, z oznako 'TMZ' na kapici in oznako '20' na telesu.
The hazard ratio (95% CI) of overall survival was 0.653 (0.476 to 0.895) for patients with KRAS wild-type tumours and 0.867 (0.670 to 1.123) for patients with KRAS mutant tumours, with no evidence of heterogeneity in treatment effect (non-significant interaction test).
Razmerje ogroženosti (95 % IZ) celokupnega preživetja je bilo 0,653 (0,476 do 0,895) pri bolnikih s tumorjem z divjim tipom gena KRAS in 0,867 (0,670 do 1,123) pri bolnikih s tumorjem z mutacijo gena KRAS, brez dokaza heterogenosti v terapevtskem učinku (nesignifikanten interakcijski test).
The hazard ratio (95% CI) of progression free survival was 0.475 (0.362 to 0.623) for patients with KRAS wild-type tumours and 0.525 (0.425 to 0.649) for patients with KRAS mutant tumours.
Razmerje ogroženosti (95 % IZ) preživetja brez napredovanja bolezni je bilo 0,475 (0,362 do 0,623) pri bolnikih s tumorjem z divjim tipom gena KRAS in 0,525 (0,425 do 0,649) pri bolnikih s tumorjem z mutacijo gena KRAS.
The hazard ratio (95% CI) of progression free survival was 0.76 (0.63 to 0.91) for ECOG performance status 0 and 0.75 (0.61 to 0.92) for ECOG performance status 1.
Razmerje ogroženosti (95 % IZ) za preživetje brez napredovanja je bilo 0,76 (0,63 do 0,91) za stanje zmogljivosti ECOG 0 in 0,75 (0,61 do 0,92) za stanje zmogljivosti ECOG 1.
The Hazard Ratio (Edoxaban 60 mg vs. warfarin) for the primary endpoint in the centres with a lower average time of INR in the target range (INR TTR) for warfarin was 0.73 – 0.80 for the lowest 3 quartiles (INR TTR ≤ 57.7% to ≤ 73.9%).
Razmerje tveganja (edoksaban 60 mg proti varfarinu) za primarni končni opazovani dogodek v centrih s krajšim povprečnim časom INR v ciljnem območju (INR TTR) za varfarin je bilo 0,73 –0,80 za najnižje 3 kvartile (INR TTR ≤ 57,7 % do ≤ 73,9 %).
The hazard ratio (HR) for overall survival was 1.59 (95 % CI for HR = 1.33 – 1.91) with a log-rank p < 0.0001 in favour of the TMZ arm.
Količnik tveganja (KT) za skupno preživetje je bil 1,59 (95 % IZ za KT= 1,33 -1,91) z logaritmičnim rangom p < 0,0001 v prid delu študije s TMZ.
The hazard ratio (HR) for overall survival was 1.59 (95 % CI for HR = 1.33 – 91) with a log-rank p < 0.0001 in favour of the TMZ arm.
Količnik tveganja (KT) za skupno preživetje je bil 1,59 (95 % IZ za KT= 1,33 -1,91) z logaritmičnim rangom p < 0,0001 v prid delu študije s TMZ.
The hazard ratio comparing dapagliflozin to comparator was 0.79 (95% Confidence interval [CI]: 0.58, 1.07), indicating that in this analysis Edistride is not associated with an increase in cardiovascular risk in patients with type 2 diabetes mellitus.
Razmerje ogroženosti z dapagliflozinom v primerjavi s primerjalnim zdravilom je bilo 0,79 (95 % interval zaupanja [IZ]: 0,58; 1,07), kar nakazuje, da v tej analizi zdravilo Edistride ni bilo povezano s povečanjem kardiovaskularnega tveganja pri bolnikih s sladkorno boleznijo tipa 2.
The hazard ratio for duration of survival (overall survival) was similar to the hazard ratio for progression-free survival (hazard ratio 0.85; 95% CI 0.64 -
Razmerje ogroženosti za trajanje preživetja (celokupnega) je bilo podobno razmerju ogroženosti za preživetje brez napredovanja bolezni (razmerje ogroženosti 0,85; 95-% interval zaupanja 0,64–1,13).
The hazard ratio for duration of survival (overall survival) was similar to the hazard ratio for progression-free survival (hazard ratio 0.85; 95% CI 0.64 - 1.13).
Razmerje ogroženosti za trajanje preživetja (celokupnega) je bilo podobno razmerju ogroženosti za preživetje brez napredovanja bolezni (razmerje ogroženosti 0,85; 95-% interval zaupanja 0,64–1,13).
The hazard ratio for duration of survival (overall survival) was similar to the hazard ratio for progression-free survival (hazard ratio 0.85; 95% CI 0.64-1.13).
Razmerje ogroženosti za trajanje preživetja (celokupnega) je bilo podobno razmerju ogroženosti za preživetje brez napredovanja bolezni (razmerje ogroženosti 0,85; 95-interval zaupanja 0,64–1,13).
The hazard ratio for survival of IV topotecan relative to CAV was
Razmerje tveganja za preživetje z intravenskim topotekanom relativno glede na kombinacijo CAV je bilo
The hazard ratio for survival of IV topotecan relative to CAV was 1.04 (95 % CI 0.78 – 1.40).
Razmerje tveganja za preživetje z intravenskim topotekanom relativno glede na kombinacijo CAV je bilo 1,04 (95 % interval zaupanja: 0,78 – 1,40).
The hazard ratio for survival of IV topotecan relative to CAV was 1.04 (95% CI 0.78 – 1.40).
Razmerje tveganj za preživetje pri zdravljenju z intravenskim topotekanom v primerjavi s kombinacijo CAV je bilo 1,04 (95 % IZ: 0,78 – 1,40).
The hazard ratio for telmisartan vs. ramipril was 1.01 (97.5 % CI 0.93 - 1.10, p (non-inferiority) = 0.0019 at a margin of 1.13).
Pri zdravljenju s telmisartanom je bilo razmerje ogroženosti v primerjavi z ramiprilom 1,01 (97,5- odstotni IZ 0,93 do 1,10, p (enakovrednost) = 0,0019 pri mejni vrednosti 1,13).
The hazard ratio for telmisartan vs. ramipril was 1.01 (97.5 % CI 0.93 - 1.10, p (non-inferiority) = 0.0019 at a margin of 1.13).
Pri zdravljenju s telmisartanom je bilo razmerje ogroženosti v primerjavi z ramiprilom 1,01 (97,5-odstotni IZ 0,93 do 1,10, p (enakovrednost) = 0,0019 pri mejni vrednosti 1,13).
The hazard ratio for telmisartan vs. ramipril was 1.01 (97.5% CI 0.93 - 1.10, p (non-inferiority) = 0.0019 at a margin of 1.13).
Razmerje ogroženost za telmisartan v primerjavi z ramiprilom je bilo 1,01 (97,5 % IZ 0,93– 1,10, p (neinferiornost) = 0,0019 ob meji 1,13).
The hazard ratio for the treatment effect was 0.85 (95% CI= 0.69, 1.03).
Nestratificirano RO = 0,84 [95 % IZ: 0,69 – 1,02] , stratificirano RO = 0,85 [95 % IZ: 0,69 – 1,03]
The hazard ratio translates into an absolute benefit, in terms of 3-year disease-free survival rate estimates of 11.8 percentage points (87.2 % versus 75.4 %) in favour of the AC→PH (Herceptin) arm.
Razmerje ogroženosti se izraža kot absolutna korist skupine, ki je prejemala AC → PH (zdravilo Herceptin), v smislu 3-letnega preživetja brez bolezni za 11,8 odstotne točke (87,2 % v primerjavi s 75,4 %).
The HbA1c change for saxagliptin 5 mg (n=56) compared to uptitrated glibenclamide plus placebo (n=27) was -0.7% at Week 76.
Sprememba HbA1c v skupini s 5 mg saksagliptina (n=56) je bila 76. teden v primerjavi s povečanim odmerkom glibenklamida v kombinaciji s placebom (n=27) -0,7 %.
The HbA1c change for saxagliptin 5 mg (n=82) compared to TZD plus placebo (n=53) was -0.9% at Week 76.
Sprememba HbA1c s 5 mg saksagliptina (n=82) je bila 76. teden v primerjavi s TZD v kombinaciji s placebom (n=53) -0,9 %.
The HbA1c change for saxagliptin 5 mg plus metformin (n=177) compared to metformin plus placebo (n=147) was -0.5% at Week 76.
Sprememba HbA1c je bila 76. teden v skupini s 5 mg saksagliptina v kombinaciji z metforminom (n=177) -0,5 % v primerjavi s skupino s placebom v kombinaciji z metforminom (n=147).
The HbA1c change for saxagliptin 5 mg plus metformin (n=31) compared to placebo plus metformin (n=15) was -0.8% at Week 102.
Po 102 tednih je bila sprememba HbA1c s 5 mg saksagliptina in metforminom (n = 31) v primerjavi s placebom in metforminom (n = 15) 0,8 %.
The HbA1c change for saxagliptin 5 mg plus metformin (n=31) compared to placebo plus metformin (n=15) was -0.8% at Week 102.
Sprememba HbA1c je bila po 102 tednih v skupini s 5 mg saksagliptina in metforminom (n=31) -0,8 % v primerjavi s skupino s placebom in metforminom (n=15).
The HbA1c change for saxagliptin compared to placebo was -0.7% at Week 24.
Sprememba HbA1c s saksagliptinom v primerjavi s placebom je bila –0,7 % 24. teden.
The HbA1c change for the saxagliptin group (n=244) compared to placebo (n=124) was -0.4% at Week 52.
Sprememba HbA1c v skupini s saksagliptinom (n = 244) je bila v 52. tednu v primerjavi s placebom (n = 124) –0,4 %.
The HbA1c change for the saxagliptin group (n=244) compared to placebo (n=124) was -0.4% at Week 52.
Sprememba HbA1c v skupini s saksagliptinom (n=244) je bila v 52. tednu v primerjavi s placebom (n=124) –0,4 %.
The HbA1c reduction was significant with once-daily administration, whether administered morning or evening.
Znižanje HbA1c je bilo značilno pri uporabi enkrat na dan, zjutraj ali zvečer.
The HCP information shall contain the following key messages:
Informacije za zdravstvene delavce morajo vsebovati naslednje ključne poudarke:
The HCPs and Blood Banks educational materials, shall contain the following key elements:
Izobraževalne materiale za zdravstvene delavce in krvno banko, ki vsebujejo naslednje ključne elemente:
The head of the cat should be held with its nose pointing upward and its mouth closed, so that it is forced to breathe through its nostrils.
Mački držite glavo tako, da bosta nosnici obrnjeni navzgor in gobček zaprt in bo prisiljena dihati skozi nosnici.
The Health Assessment Questionnaire (HAQ; scale 0-3) was used to measure patients’ average change from baseline scores over time, in physical function.
Vprašalnik za oceno zdravstvenega stanja (HAQ-Health Assessment Questionnaire, lestvica 0 - 3) so uporabljali za merjenje povprečne spremembe vrednosti za funkcijo sklepov s časom, v primerjavi z začetnimi vrednostmi.
The Health Assessment Questionnaire (HAQ; scale 0-3) was used to measure patients’ average change from baseline scores over time, in physical function.
Vprašalnik za oceno zdravstvenega stanja (HAQ-Health Assessment Questionnaire, lestvica 0-3) so uporabljali za merjenje povprečne spremembe vrednosti za funkcijo sklepov s časom, v primerjavi z začetnimi vrednostmi.
the health of your liver other medicines you are taking.
zdravstveno stanje vaših jeter, druga zdravila, ki jih jemljete.
The healthcare institution’s standard sterile operating procedures for skin preparation must be followed to avoid microbial contamination and infection.
Da bi preprečili kontaminacijo z mikrobi in okužbe, je treba upoštevati standardni operativni postopek za sterilno pripravo kože, ki velja v zdravstveni ustanovi.
The Healthcare Professional Guide
Priročnik za zdravstvene delavce.
The Healthcare Professional information pack should be a step by step treatment guide that includes information on the following key elements:
Informacijski paket za zdravstveno osebje mora biti pripravljen v obliki vodnika, ki po korakih opisuje zdravljenje, in vsebovati informacije o naslednjih ključnih elementih:
The healthcare professional information regarding Volibris should contain the following key elements:
Informacije o zdravilu Volibris za zdravstvene delavce morajo vključevati naslednje ključne elemente: